false 0001130166 0001130166 2024-09-04 2024-09-04 0001130166 us-gaap:CommonStockMember 2024-09-04 2024-09-04 0001130166 us-gaap:PreferredStockMember 2024-09-04 2024-09-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 4, 2024

 

CYCLACEL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   0-50626   91-1707622
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

200 Connell Drive, Suite 1500

Berkeley Heights, NJ 07922

(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (908) 517-7330

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.001 per share CYCC The Nasdaq Capital Market
Preferred Stock, $0.001 par value CYCCP The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

Item 8.01 Other Events.

 

On September 4, 2024, the Board of Directors of Cyclacel Pharmaceuticals, Inc. (the “Company”) passed a resolution to suspend payment of the quarterly cash dividend on the Company’s 6% Convertible Exchangeable Preferred Stock (the “Preferred Stock”) scheduled for November 1, 2024. The Board of Directors will continue to evaluate the payment of a quarterly cash dividend on a quarterly basis.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

CYCLACEL PHARMACEUTICALS, INC.  
   
By: /s/ Paul McBarron  
Name:   Paul McBarron  
Title: Executive Vice President-Finance,  
  Chief Financial Officer and Chief Operating Officer  

 

Date: September 6, 2024

 

 

 

v3.24.2.u1
Cover
Sep. 04, 2024
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 04, 2024
Entity File Number 0-50626
Entity Registrant Name CYCLACEL PHARMACEUTICALS, INC.
Entity Central Index Key 0001130166
Entity Tax Identification Number 91-1707622
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 200 Connell Drive
Entity Address, Address Line Two Suite 1500
Entity Address, City or Town Berkeley Heights
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07922
City Area Code 908
Local Phone Number 517-7330
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol CYCC
Security Exchange Name NASDAQ
Preferred Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Preferred Stock, $0.001 par value
Trading Symbol CYCCP
Security Exchange Name NASDAQ
Cyclacel Pharmaceuticals (NASDAQ:CYCCP)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Cyclacel Pharmaceuticals Charts.
Cyclacel Pharmaceuticals (NASDAQ:CYCCP)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Cyclacel Pharmaceuticals Charts.